(MedPage Today) -- BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage ...
(MedPage Today) -- BERLIN -- Patients with cisplatin-ineligible bladder cancer had huge reductions in clinical events and cancer death when ...
(MedPage Today) -- "It could be cheap, but it still could be poison." -- Stuart Weinerman, MD, of Northwell Health ...
(MedPage Today) -- BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients ...
Progression-free and overall survival outcomes in patients with cancer treated with immunotherapy could be related to thymic health. Medscape Medical ...
(MedPage Today) -- ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the need ...
(MedPage Today) -- BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant ...
(MedPage Today) -- Recently, I was honored by the New York Celtic Medical Society with their "Healer" award -- a ...
mRNA vaccines are increasingly showing their potential to transform medicineJOSEPH PREZIOSO/AFP via Getty Images The mRNA covid-19 vaccines seem to ...
Rugby professional Jonny Murphy was forced to retire early on medical grounds at just 30 years old - so he ...
(MedPage Today) -- ATLANTA -- Mortality rates from Clostridioides difficile-related infections have fallen steadily since 2016, but the condition continues ...
(MedPage Today) -- ATLANTA -- Having shingles boosted the risk of major adverse cardiovascular events (MACE) such as vascular dementia, ...
(MedPage Today) -- BERLIN -- Belzutifan (Welireg) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm phase ...
(MedPage Today) -- You passed medical training, now see if you can pass our weekly quiz Source link : https://www.medpagetoday.com/quizzes/news-quiz/118005 ...
(MedPage Today) -- BERLIN -- Almost half of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) have lived 7 ...
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for ...
(MedPage Today) -- BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor ...
Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care. Medscape Medical News Source link ...
(MedPage Today) -- BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening ...
(MedPage Today) -- As I'm about to get out of my car and head into the hospital for my shift, ...
